Anupam Rasayan to acquire 26% stake in Bliss GVS Pharma for ₹829 Crore
Anupam Rasayan India Limited, with Mates Visa Consultancy, is making an open offer to acquire 26% stake in Bliss GVS Pharma for ₹829.03 crore. The offer price is ₹299 per share. The tendering period will be from July 28 to August 10, 2026. An escrow amount of ₹160 crore has been arranged.
The acquisition involves a substantial stake (26%) in another company for a significant amount (₹829 crore), which is material to Anupam Rasayan India Limited's financial and strategic standing.
The announcement details a significant acquisition, which is generally viewed positively as it indicates growth and expansion for the acquiring company.
Anupam Rasayan India Limited (Acquirer), along with Mates Visa Consultancy Private Limited (PAC), has announced an open offer to acquire up to 2,77,26,848 equity shares of Bliss GVS Pharma Limited (Target Company). This represents 26.00% of the expanded voting share capital of the Target Company. The offer price for each equity share is fixed at ₹299.00, resulting in a maximum potential acquisition value of ₹829.03 crore.
The open offer is being made pursuant to the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The schedule of activities for the offer includes the dispatch of the Letter of Offer to public shareholders by July 21, 2026, with the tendering period commencing on July 28, 2026, and closing on August 10, 2026.
Anupam Rasayan India Limited has made necessary financial arrangements, including an escrow amount of ₹160 crore, to fund this open offer. The company, along with the PAC, will acquire the shares from the public shareholders of Bliss GVS Pharma Limited.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.